ArticleFrontiers in psychiatry2019
Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics.
Article in Frontiers in psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- How can we facilitate research on the risks and potential benefits of novel psychoactive substances?EClinicalMedicine · 2026Review
- Self-inflicted transorbital intracranial foreign body following ingestion of hallucinogenic psilocybin mushrooms.American journal of ophthalmology case reports · 2025Article
- Psychedelics and Suicide-Related Outcomes: A Systematic Review.Journal of clinical medicine · 2025Review
- From chaos to kaleidoscope: Exploring factors in psychedelic self-treatment for mental health conditions.Journal of psychopharmacology (Oxford, England) · 2024Article
- Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension.Frontiers in psychiatry · 2024Article
- Does LSD confer lasting psychological resilience? an investigation of naturalistic users experiencing job loss.PloS one · 2024Article
- Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample.Scientific reports · 2023Article
- Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests.Frontiers in psychiatry · 2023Article
- Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents.Scientific reports · 2022Article
- Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality.Scientific reports · 2022Article
- Prevalence and associations of classic psychedelic-related seizures in a population-based sample.Drug and alcohol dependence · 2022Article
- Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults.Addictive behaviors · 2022Article
- A narrative synthesis of research with 5-MeO-DMT.Journal of psychopharmacology (Oxford, England) · 2022Review
- Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States.Frontiers in psychiatry · 2022Article
- The association between naturalistic use of psychedelics and co-occurring substance use disorders.Frontiers in psychiatry · 2022Article
- On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review.ACS pharmacology & translational science · 2021Review
- Associations between lifetime classic psychedelic use and markers of physical health.Journal of psychopharmacology (Oxford, England) · 2021Article
- Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes.Frontiers in psychiatry · 2021Article
- Combining Neurobehavioral Analysis andACS chemical neuroscience · 2020Article
- Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.Journal of psychoactive drugsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe majority of contemporary psychedelic research has focused on ayahuasca, lysergic acid diethylamide, and psilocybin, though there are hundreds of novel psychedelic compounds that may have clinical utility. The purpose of the present study was to evaluate the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics
methodsWe tested the unique associations of lifetime classic and novel phenethylamine, tryptamine, and lysergamide psychedelics with past month psychological distress and past year suicidality among respondents pooled from years 2008-2017 of the National Survey on Drug Use and Health (weighted N = 260,964,827).
resultsLifetime classic tryptamine use was associated with a decreased odds of past month psychological distress [aOR = 0.76; (0.69-0.83)] and past year suicidal thinking [aOR = 0.79; (0.72-0.87)]. Lifetime novel phenethylamine use, on the other hand, was associated with an increased odds of past year suicidal thinking [aOR = 1.44; (1.06-1.95)] and past year suicidal planning [aOR = 1.60; (1.06-2.41)]. No other significant associations were found. DISCUSSION AND
conclusionsThese findings, which may be driven by differences in pharmacodynamics, suggest that classic tryptamines may hold the greatest therapeutic potential of the psychedelics, whereas novel phenethylamines may pose risk for harm. The present findings thus support continued research on the clinical application of classic tryptamines. Though the current results caution against the clinical utility of novel phenethylamines, further study of these and other novel psychedelic substances is nonetheless warranted to better understand their potential application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.